(Q44532948)

3 December 2017

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase (English)

1 reference

3 December 2017

Peter Angus

1

1 reference

3 December 2017

Rhys Vaughan

2

1 reference

3 December 2017

Shelly Xiong

3

1 reference

3 December 2017

Huiling Yang

4

1 reference

3 December 2017

William Delaney

5

1 reference

3 December 2017

Craig Gibbs

6

1 reference

3 December 2017

Carol Brosgart

7

1 reference

3 December 2017

Danielle Colledge

8

1 reference

3 December 2017

Rosalind Edwards

9

1 reference

3 December 2017

Anna Ayres

10

1 reference

3 December 2017

Angeline Bartholomeusz

11

1 reference

3 December 2017

Stephen Locarnini

12

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

3 December 2017

1 reference

3 December 2017

125

1 reference

3 December 2017

292-297

1 reference

3 December 2017

2

1 reference

Treatment of HBe antigen-positive chronic hepatitis B.

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Treatment of HBeAg-negative chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Suppressing hepatitis B without resistance--so far, so good

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Hepatitis B e antigen-negative chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Clinical experience with famciclovir against hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

Combination chemotherapy for hepatitis B virus: the final solution?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Naturally occurring variants of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900939-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(03)00939-9

1 reference

3 December 2017

1 reference